References
1. Beers MH and Berkow R, eds. The Merck
Manual, 17th ed. Whitehouse Station, NJ: Merck and Co., Inc., 1999, 1692.
2. Coughlin SS,
Pearle DL, Baughman KL, et al. Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The
Washington, DC Dilated Cardiomyopathy Study. Ann Epidemiol 1994;4(1):67–74.
3. Post WS, Larson MG, Levy D. Hemodynamic
predictors of incident hypertension. The Framingham Heart Study. Hypertension
1994;24(5):585–90.
4. McKenna CJ, Codd MB, McCann HA, Sugrue DD. Alcohol consumption and idiopathic dilated cardiomyopathy: a case control study. Am Heart J 1998;135(5 Pt 1):833–7.
5. Hoyumpa AM. Mechanisms of vitamin deficiencies in alcoholism. Alcohol Clin Exp Res 1986;10(6):573–81.
6. Lieber CS. Alcohol-nutrition interaction: 1984 update. Alcohol 1984;1(2):151–7.
7. Klatsky AL. The cardiovascular effects of alcohol. Alcohol 1987;Suppl 1:117–24.
8. Friedman HS. Cardiovascular effects of alcohol with particular reference to the heart. Alcohol 1984;1(4):333–9.
9. Urbano-Marquez A, Estruch R, Fernandez-Sola J, et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 1995;274(2):149–54.
10. Valgaeren G, Conraads V, Colpaert C, et al. Sudden death in hypertrophic cardiomyopathy: risk stratification and prevention. Acta Cardiol 1998;53(1):23–9.
11. Belardinelli R, Georgiou D, Cianci G, et al. Effects of exercise training on left ventricular filling at rest and during exercise in patients with ischemic cardiomyopathy and severe left ventricular systolic dysfunction. Am Heart J 1996;132(1 Pt 1):61–70.
12. Belardinelli R, Georgiou D, Cianci G, et al. Exercise training improves left ventricular diastolic filling in patients with dilated cardiomyopathy. Clinical and prognostic implications. Circulation 1995;91(11):2775–84.
13. Wielenga RP, Erdman RA, Huisveld IA, et al. Effect of exercise training on quality of life in patients with chronic heart failure. J Psychosom Res 1998;45(5):459–64.
14. Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998;98(24):2709–15.
15. Coughlin SS, Neaton JD, Sengupta A, Kuller LH. Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1994;139(2):166–72.
16. Hartz AJ, Ratner ER, Sinoway LI, Bartholomew MJ. Smoking and idiopathic congestive cardiomyopathy. Jpn Heart J 1996;37(3):401–7.
17. Juilliere Y, Danchin N, Briancon S, et al. Dilated cardiomyopathy: long-term follow-up and predictors of survival. Int J Cardiol 1988;21(3):269–77.
18. Metayer C, Coughlin SS, Mather FJ. Does cigarette smoking paradoxically increase survival in idiopathic dilated cardiomyopathy? The Washington, D.C., Dilated Cardiomyopathy Study. Cardiology 1996;87(6):502–8.
19. Manzoli U, Rossi E, Littarru GP, et al. Coenzyme Q10 in dilated cardiomyopathy. Int J Tissue React 1990;12(3):173–8.
20. Pogessi L, Galanti G, Comeglio M, et al. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. Curr Ther Res 1991;49:878–86.
21. Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci U S A 1985;82:4240–4.
22. Ma A, Zhang W, Liu Z. Effect of protection and repair of injury of mitochondrial membrane-phospholipid on prognosis in patients with dilated cardiomyopathy. Blood Press Suppl 1996;3:53–5.
23. Belardinelli R, Georgiou D, Cianci G, et al. Effects of exercise training on left ventricular filling at rest and during exercise in patients with ischemic cardiomyopathy and severe left ventricular systolic dysfunction. Am Heart J 1996;132(1 Pt 1):61–70.
24. Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990;100:70–8.
25. Permanetter B, Rossey W, Weingartner F, et al. Lack of effectiveness of coenzyme Q10 (Ubiquinone) in long-term treatment of dilated cardiomyopathy. Z Kardiol 1989;78:360–5 [in German].
26. Paulson DJ. Carnitine deficiency-induced cardiomyopathy. Mol Cell Biochem 1998;180(1–2):33–41.
27. Winter S, Jue K, Prochazka J, et al. The role of L-carnitine in pediatric cardiomyopathy. J Child Neurol 1995;10 Suppl 2:S45–51.
28. Kothari SS, Sharma M. L-carnitine in children with idiopathic dilated cardiomyopathy. Indian Heart J 1998;50:59–61.
29. Kittleson MD, Keene B, Pion PD, Loyer CG. Results of the multicenter spaniel trial (MUST): taurine- and carnitine-responsive dilated cardiomyopathy in American cocker spaniels with decreased plasma taurine concentration. J Vet Intern Med 1997;11:204–11.
30. Pion PD, Kittleson MD, Thomas WP, et al. Response of cats with dilated cardiomyopathy to taurine supplementation. J Am Vet Med Assoc 1992;201:275–84.
31. Auzepy P, Blondeau M, Richard C, et al. Serum selenium deficiency in myocardial infarction and congestive cardiomyopathy. Acta Cardiol 1987;42:161–6.
32. Oster O, Prellwitz W, Kasper W, Meinertz T. Congestive cardiomyopathy and the selenium content of serum. Clin Chim Acta 1983;29(128):125–32.
33. Xu GL, Wang SC, Gu BQ, et al. Further investigation on the role of selenium deficiency in the aetiology and pathogenesis of Keshan disease. Biomed Environ Sci 1997;10:316–26.
34. Neve J. Selenium as a risk factor for cardiovascular diseases. J Cardiovasc Risk 1996;3:42–7.
35. Collipp PJ, Chen SY. Cardiomyopathy and selenium deficiency in a two-year-old girl. N Engl J Med 1981;304:1304–5 [letter].
36. Raines DA, Kinsara AJ, Eid Fawzy M, et al. Plasma and urinary selenium in Saudi Arabian patients with dilated cardiomyopathy. Biol Trace Elem Res 1999;69:59–68.
37. Ikram H, Crozier IG, Webster M, Low CJ. The role of selenium deficiency in occidental dilated cardiomyopathy. N Z Med J 1989;102:100–2.
38. Chou HT, Yang HL, Tsou SS,et al. Status of trace elements in patients with idiopathic dilated cardiomyopathy in central Taiwan. Chung Hua I Hsueh Tsa Chih (Taipei) 1998;61:193–8.
39. Weikl A, Assmus KD, Neukum-Schmidt A, et al. Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure. Fortschr Med 1996;114:291–6 [in German].
40. Weihmayr T, Ernst E. Therapeutic effectiveness of Crataegus. Fortschr Med 1996;114:27–9 [in German].
41. Leuchtgens H. Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study. Fortschr Med 1993;111:352–4 [in German].
42. Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery disease. Indian Heart J 1997;49:507–10.
43. Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. Int J Cardiol 1995;49:191–9.
44. Lindner E, Dohadwalla AN, Bhattacharya BK. Positive inotropic and blood pressure lowering activity of a diterpene derivative isolated from Coleus forskohli: forskolin. Arzneimittelforschung 1978;28:284–9.
45. Baumann G, Felix S, Sattelberger U, Klein G. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy—a comparative study with dobutamine and sodium nitroprusside. J Cardiovasc Pharmacol 1990;16:93–100.
46. Kramer W, Thormann J, Kindler M, Schlepper M. Effects of forskolin on left ventricular function in dilated cardiomyopathy. Arzneimittelforschung 1987;37:364–7.
47. Takeo S, Tanonaka K, Hirai K, et al. Beneficial effect of tan-shen, an extract from the root of Salvia, on post-hypoxic recovery of cardiac contractile force. Biochem Pharmacol 1990 40:1137–43.
48. Bai YR, Wang SZ. Hemodynamic study on nitroglycerin compared with Salvia miltiorrhiza. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1994;14:24–5 [in Chinese].
49. Xing ZQ, Zeng XC, Yi CT. Effect of Salvia miltiorrhiza on serum lipid peroxide, superoxide dismutase of the patients with coronary heart disease. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1996;16:287–8 [in Chinese].